目的 觀察紫龍金片聯(lián)合多西他賽注射液和注射用奈達(dá)鉑治療局部晚期非小細(xì)胞肺癌的臨床療效。方法 選取2014年2月—2015年7月于天津市胸科醫(yī)院呼吸與危重癥科住院的局部晚期非小細(xì)胞肺癌確診患者78例,隨機(jī)分為對(duì)照組和治療組,每組各39例。對(duì)照組給予多西他賽注射液75 mg/m²,溶入250 mL生理鹽水,第1天靜脈滴注;注射用奈達(dá)鉑80 mg/m²,溶入500 mL生理鹽水,第2天靜脈滴注。治療組在對(duì)照組治療基礎(chǔ)上口服紫龍金片2.6 g,3次/d。21 d為1個(gè)周期,患者化療2個(gè)周期。評(píng)估肺癌患者的近期療效,并比較患者的生活質(zhì)量和T淋巴細(xì)胞亞群水平,對(duì)毒副反應(yīng)進(jìn)行評(píng)價(jià)。結(jié)果 化療后對(duì)照組和治療組的緩解率分別為15.4%、20.5%,疾病控制率分別為84.6%、92.3%,兩組近期療效比較差異無(wú)統(tǒng)計(jì)學(xué)意義。治療后治療組軀體功能、角色功能、社會(huì)功能和總健康評(píng)分較治療前增加(P<0.05),疲倦、氣促評(píng)分較治療前下降(P<0.05);兩組治療后軀體功能、角色功能、社會(huì)功能、總健康、疲倦、氣促評(píng)分比較差異均具有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,治療組CD8顯著降低,CD4/CD8顯著升高,同組治療前后差異有統(tǒng)計(jì)學(xué)意義(P<0.05、0.01)。治療組CD4、CD4/CD8改善程度優(yōu)于對(duì)照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.01)。治療組化療所致的惡心嘔吐、白細(xì)胞減少癥狀均輕于對(duì)照組(P<0.05)。結(jié)論 紫龍金片聯(lián)合多西他賽注射液和注射用奈達(dá)鉑治療局部晚期非小細(xì)胞肺癌具有較好的臨床療效,可以改善患者的生活質(zhì)量,提高患者機(jī)體免疫力,減輕化療的毒副作用,值得在臨床上進(jìn)一步推廣和應(yīng)用。

Objective To observe the clinical curative effect of Zilongjin Tablets combined with Docetaxel Injection and Nedaplatin for injection in treatment of locally advanced non small cell lung cancer. Methods Patients (78 cases) with locally advanced non small cell lung cancer in Department of Respiration and Critical Care Medicine of Tianjin Chest Hospital from February 2014 to July 2015 were randomly divided into control and treatment groups, and each group had 39 cases. The patients in the control group were iv administered with Docetaxel Injection 75 mg/m² in the first day, added into 0.9% normal saline 250 mL. And the control group was also iv administered with Nedaplatin for injection 80 mg/m² in the second day, added into 0.9% normal saline 500 mL. The patients in the treatment group were po administered with Zilongjin Tablets 2.6 g on the basis of the control group, three times daily. A course of treatment included 3 weeks, and the patients in two groups were treated for two courses. After treatment, the efficacy was evaluated, and quality of life, levels of T lymphocyte subsets, and side effects in two groups before and after treatment were compared. Results After treatment, the remission rates in the control and treatment groups were 15.4% and 20.5%, and the control rates were 84.6% and 92.3% respectively, and there was no difference between two groups. After treatment, scores of physical function, role function, social function, and general health in treatment group were significantly increased (P < 0.05), but scores of fatigue and shortness of breath were significantly decreased (P < 0.05). After treatment, scores of physical function, role function, social function, general health, fatigue, and shortness of breath in the treatment group were better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, levels of CD8 in the treatment group were obviously decreased,but CD4/CD8 was significantly increased, and the difference was statistically significant in the same group (P < 0.05, 0.01). These observational indexes in the treatment group were better than those in the control group, with significant difference between two groups (P < 0.05). Nausea and vomiting and leucopenia in treatment group were better than those in the control group (P < 0.05). Conclusion Zilongjin Tablets combined with Docetaxel Injection and Nedaplatin for injection has a clinical curative effect in the treatment of locally advanced non small cell lung cancer, and can improve quality of life, improve body immunity, and reduce side effects, which has a certain clinical application value.